Get the Stockscreener App
52.14
4.16%
2.08
After Hours:
52.55
0.41
+0.79%
Corcept Therapeutics Inc stock is traded at $52.14, with a volume of 1.23M.
It is up +4.16% in the last 24 hours and up +14.77% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
See More
Previous Close:
$50.06
Open:
$50
24h Volume:
1.23M
Relative Volume:
1.48
Market Cap:
$5.24B
Revenue:
$523.53M
Net Income/Loss:
$118.02M
P/E Ratio:
64.37
EPS:
0.81
Net Cash Flow:
$124.84M
1W Performance:
+8.15%
1M Performance:
+14.77%
6M Performance:
+112.64%
1Y Performance:
+103.51%
1-Day Range:
$49.51
$52.35
1-Week Range:
$42.01
$52.35
52-Week Range:
$20.84
$52.35
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
149 COMMONWEALTH DRIVE, MENLO PARK
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Here is Why Growth Investors Should Buy Corcept (CORT) Now - Yahoo Finance
Corcept (CORT) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance Australia
Corcept Stock At New High; Will The Upcoming Regulatory And Clinical Trial Catalysts Take It Higher? - RTTNews
Roman Butler Fullerton & Co. Sells 10,466 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Creative Planning Acquires 841 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics (NASDAQ:CORT) Reaches New 1-Year HighStill a Buy? - MarketBeat
Corcept Therapeutics stock soars to all-time high of $50.23 By Investing.com - Investing.com Australia
Corcept Therapeutics stock soars to all-time high of $50.23 - Investing.com
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade - Yahoo Canada Finance
Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why - Yahoo Canada Finance
What is HC Wainwright’s Forecast for CORT FY2024 Earnings? - Defense World
Research Analysts Issue Forecasts for CORT FY2024 Earnings - MarketBeat
What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View - MSN
Corcept Therapeutics (CORT) Stock Declines Amid Market Activity - GuruFocus.com
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy? - MSN
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.2%Here's What Happened - MarketBeat
FY2026 Earnings Estimate for CORT Issued By HC Wainwright - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2024 Earnings Call Transcript - Insider Monkey
Corcept’s relacorilant GRADIENT trial misses primary endpoint - Yahoo Finance
Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Corcept Therapeutics reports robust Q3 growth, raises guidance - Investing.com Canada
Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Expansion - GuruFocus.com
Corcept Therapeutics Inc (CORT) Q3 2024 Earnings: EPS of $0.41 B - GuruFocus.com
HC Wainwright Reiterates Buy Rating for Corcept Therapeutics (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates - MSN
Corcept: Q3 Earnings Snapshot - Milford Mirror
Corcept reports robust revenue growth in Q3 By Investing.com - Investing.com Canada
abrdn plc Purchases 142,310 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update - StockTitan
Earnings Preview: Corcept Therapeutics - Benzinga
Boston Trust Walden Corp Sells 69,924 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (CORT) Set to Announce Earnings on Wednesday - MarketBeat
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Yahoo Finance
Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength? - MSN
Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise - Yahoo Finance
Corcept stock stays a buy, with analyst eyeing validation of relacorilant’s cancer-fighting mechanism - Investing.com UK
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) PT at $65.25 - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Position Reduced by Exchange Traded Concepts LLC - Defense World
Exchange Traded Concepts LLC Decreases Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Corcept Therapeutics (CORT) Stock Jumps Over 5% Amid Solid Finan - GuruFocus.com
HC Wainwright Increases Corcept Therapeutics (NASDAQ:CORT) Price Target to $80.00 - MarketBeat
Corcept Therapeutics stock target raised, buy rating on Cushing's franchise growth - Investing.com Canada
Key Takeaways From Corcept Therapeutics Analyst Ratings - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Sets New 12-Month HighHere's Why - MarketBeat
Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High? - Yahoo Finance
Corcept Therapeutics stock hits all-time high at $47.81 - Investing.com
Corcept Therapeutics stock hits all-time high at $47.81 By Investing.com - Investing.com UK
Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):